[研究-ALPHA:膀调节性和α抑制剂在LUTS联合治疗中的作用]
G Spivak L1,2, O Morozov A1,2, R Bogatova S1,2
1Institute of Urology and Reproductive Health of FGAOU VO I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Urologiia (Moscow, Russia : 1999)
|May 16, 2025
概括
将Vesusten添加到α抑制剂中显著改善了良性前列腺增生 (BPH) 和过活性膀 (OAB) 的男性下泌尿道症状 (LUTS). 这种组合疗法有效地减少了刺激症状,改善了尿流,只观察到轻微的副作用.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有良性前列腺增生症 (BPH) 的男性的下泌尿道症状 (LUTS) 是复杂的,通常与过度活跃的膀 (OAB) 相关.
- 标准的α-1-阻断剂单疗法在解决与OAB相关的刺激性LUTS方面显示出有限的疗效.
- 牛尿膀聚 (Vesusten) 已经证明在管理OAB症状方面具有潜力.
研究的目的:
- 评估在BPH患者中将α-1-阻断剂与Vesusten结合用于LUTS的疗效和安全性.
- 为了比较这种组合疗法与标准的α-1-阻断剂单疗法.
主要方法:
- 这是一项开放的,前性的,随机的,单中心的研究.
- 100名患有LUTS的BPH患者被随机分为两组.
- 主要组每天接受α-1-阻断剂加肌内Vesusten (10剂,每周3次);对照组仅接受α-1-阻断剂.
主要成果:
- 与单一治疗相比,组合疗法显著改善了国际前列腺症状得分 (IPSS) 和OAB问卷 (OAB-q) 的得分 (p<0.001).
- 随着联合治疗 (p<0.001) 观察到排尿频率和排尿后残留体积的显著减少,以及排尿体积的增加.
- 在组合组中,最大 (Qmax) 和平均 (Qave) 尿流率的改善显著更大 (p<0.001).
结论:
- 与Vesusten和α-1-阻断剂的联合治疗在OABBPH患者的刺激性LUTS的管理中提供了显著的益处.
- 这种方法导致症状得分,尿液流量计和膀空气参数的实质性改善.
- 治疗耐受性很好,只有轻微的局部不良事件,不需要停止治疗.
相关概念视频
01:26The Micturition Reflex
337
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
337
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
514
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
514
01:21Drugs for Treatment of Constipation-Predominant IBS
117
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
01:17Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126
01:23Urinary Bladder
257
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
257
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331